Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 7707 results

  1. Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

    Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.

  2. Tenecteplase for treating acute ischaemic stroke (TA990)

    Evidence-based recommendations on tenecteplase (Metalyse) for treating acute ischaemic stroke in adults.

  3. Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.

  4. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

    Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.

  5. Guidance on the extraction of wisdom teeth (TA1)

    Evidence-based recommendations on removing wisdom teeth in adults.

  6. Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

    Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.

  7. Guidance on the use of liquid-based cytology for cervical screening (TA69)

    Evidence-based recommendations on using liquid-based cytology for cervical screening in adults.

  8. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

    Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults.

  9. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

  10. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

  11. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after total hip or total knee replacement in adults.

  12. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

    Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.

  13. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

  14. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.

  15. Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

    Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.